Clinical trial · Observational
Patient Selection for Hypoxia Modifying Treatments in Larynx Carcinomas
Patient Selection for Hypoxia Modifying Treatments Based on Functional Microregional Imaging of Tumor Vasculature, Oxygenation and Proliferation in Squamous Cell Carcinoma of the Larynx
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to identify in a prospective manner microregional profiles of oxygenation and proliferation based on exogenous and endogenous markers that are predictive for outcome of radiotherapy in squamous cell carcinoma of the larynx and to investigate if these profiles can identify patients that are most likely to benefit from hypoxia modifying treatment strategies like ARCON (Accelerated radiotherapy combined with carbogen breathing and nicotinamide).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Larynx Cancer | Malignant Laryngeal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Pathological confirmed squamous cell carcinoma of the larynx. * TNM-classification (UICC 1997, appendix I): * T3-4 glottic or supraglottic carcinoma * T2 glottic carcinoma with impaired cord mobility or subglottic extension * T2 supraglottic carcinoma with invasion of mucosa of base of tongue or vallecula or invasion of the medial wall of the piriform sinus. * any N-stage, M0. * WHO performance status 0 or 1. * Age \> 18 years. * Written informed consent. * Treatment in the ARCON phase III trial Exclusion Criteria: * Prior or concurrent treatment for this tumour. * Severe stridor and adequate debulking of airway not possible. * Impaired renal function: serum creatinine above upper normal limit. * Use of nephrotoxic medication (including ACE-inhibitors) that cannot be discontinued for the duration of the radiation treatment. * Impaired hepatic function: ASAT and ALAT more than 1.5 times the upper normal limit. * Use of anti-convulsants that cannot be discontinued for the duration of the radiation treatment. * History of malignancy during the previous 5 years except basal cell carcinoma of skin, carcinoma in situ of the cervix, or superficial bladder neoplasm (pTa).
References
Publications (0)
Data not yet available